H. Lang

发表

Premature aortic smooth muscle cell differentiation contributes to matrix dysregulation in Marfan Syndrome

I. Pipinos, Jeffrey S. Carson, Zhibo Liu, 2017, PloS one.

Induction of human blood group a antigen expression on mouse cells, using lentiviral gene transduction.

J. Platt, J. Medin, L. West, 2010, Human gene therapy.

Transcriptomic analysis reveals optimal cytokine combinations for SARS-CoV-2-specific T cell therapy products

Christopher A. Lazarski, P. Hanley, C. Bollard, 2022, Molecular Therapy - Methods & Clinical Development.

Outcome of donor-derived TAA-T cell therapy in patients with high-risk or relapsed acute leukemia post allogeneic BMT

N. Zhang, P. Hanley, C. Bollard, 2022, Blood advances.

Notice of Retraction Finite Element Analysis of Stent Deployment in a Stenotic Artery and Their Interactions

Stacey R. Froemming, L. Gu, Shijia Zhao, 2011 .

Spike-directed vaccination elicits robust spike-specific T-cell response, including to mutant strains

Christopher A. Lazarski, C. Bollard, P. Burbelo, 2021, Cytotherapy.

Comparable transforming growth factor beta-mediated immune suppression in ex vivo-expanded natural killer cells from cord blood and peripheral blood: implications for adoptive immunotherapy.

C. Cruz, C. Bollard, M. Long, 2022, Cytotherapy.

Highly conserved pattern of recognition of influenza A wild-type and variant CD8+ CTL epitopes in HLA-A2+ humans and transgenic HLA-A2+/H2 class I-deficient mice.

N. Hu, J. Chamberlain, H. Lang, 2005, Vaccine.

Anoxic Ventilation Improves Systemic Perfusion During Extracorporeal Circulation With Uncontrolled Systemic-to-Pulmonary Shunt

J. Hammel, H. Lang, K. Duncan, 2007, ASAIO journal.

Robust Antibody and T Cell Responses to SARS-CoV-2 in Patients with Antibody Deficiency

Christopher A. Lazarski, L. Notarangelo, C. Bollard, 2021, Journal of Clinical Immunology.

Spike-Directed Vaccination Elicits Robust Spike-Specific T cell Responses Including to Mutant Strains

Christopher A. Lazarski, C. Bollard, P. Burbelo, 2021 .

HPV-specific T-cells can be generated from naïve T cells for use as immunotherapeutic strategy for immunocompromised patients

E. Fuchs, Powell, C. Trimble, 2019 .

Co-transducing B7H3 CAR-NK cells with the DNR preserves their cytolytic function against GBM in the presence of exogenous TGF-β

Christopher A. Lazarski, C. Cruz, C. Bollard, 2022, Molecular therapy. Methods & clinical development.

T-Cell Therapeutics Targeting Human Parainfluenza Virus 3 Are Broadly Epitope Specific and Are Cross Reactive With Human Parainfluenza Virus 1

Christopher A. Lazarski, C. Bollard, C. Lazarski, 2020, Frontiers in Immunology.

Human parainfluenza virus-3 can be targeted by rapidly ex vivo expanded T lymphocytes.

P. Hanley, C. Cruz, C. Bollard, 2016, Cytotherapy.

SARS-CoV-2–specific T cells are rapidly expanded for therapeutic use and target conserved regions of the membrane protein

Christopher A. Lazarski, N. Zhang, P. Hanley, 2020, Blood.

SARS-CoV-2-Specific T Cell Responses Are Stronger in Children With Multisystem Inflammatory Syndrome Compared to Children With Uncomplicated SARS-CoV-2 Infection

Christopher A. Lazarski, R. DeBiasi, C. Bollard, 2022, Frontiers in Immunology.

Characterization of natural killer cells expressing markers associated with maturity and cytotoxicity in children and young adults with sickle cell disease

C. Bollard, L. Kean, R. Nickel, 2019, Pediatric blood & cancer.

Immunotherapy of Relapsed and Refractory Solid Tumors With Ex Vivo Expanded Multiantigen-Associated Specific Cytotoxic T Lymphocytes: A Phase I Study.

S. Darko, P. Hanley, C. Cruz, 2019, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Human MHC Class I Transgenic Mice Deficient for H2 Class I Expression Facilitate Identification and Characterization of New HLA Class I-Restricted Viral T Cell Epitopes1

N. Hu, J. Chamberlain, H. Lang, 2002, The Journal of Immunology.

SARS-CoV-2–specific T cells are rapidly expanded for therapeutic use and target conserved regions of the membrane protein

Christopher A. Lazarski, P. Hanley, C. Bollard, 2020, Blood.

Mycobacteria-Specific T Cells May Be Expanded From Healthy Donors and Are Near Absent in Primary Immunodeficiency Disorders

S. Holland, P. Hanley, C. Cruz, 2019, Front. Immunol..

Human papilloma virus-specific T cells can be generated from naïve T cells for use as an immunotherapeutic strategy for immunocompromised patients.

C. Bollard, E. Fuchs, C. Trimble, 2018, Cytotherapy.

Identification of novel HLA-restricted preferentially expressed antigen in melanoma peptides to facilitate off-the-shelf tumor-associated antigen-specific T-cell therapies.

P. Hanley, C. Cruz, A. Barrett, 2021, Cytotherapy.

T‐cell receptor sequencing demonstrates persistence of virus‐specific T cells after antiviral immunotherapy

Christopher A. Lazarski, D. Douek, S. Darko, 2019, British journal of haematology.

Outcomes following posttransplant virus-specific T-cell therapy in patients with sickle cell disease

P. Hanley, C. Bollard, K. Mahadeo, 2022, Blood advances.

Spike-Directed Vaccination Elicits Robust Spike-Specific T cell Responses Including to Mutant Strains

P. Burbelo, C. Lazarski, A. Geiger, 2021 .

Notice of RetractionFinite Element Analysis of Stent Deployment in a Stenotic Artery and Their Interactions

Stacey R. Froemming, L. Gu, Shijia Zhao, 2011, 2011 5th International Conference on Bioinformatics and Biomedical Engineering.

EPCT-15. THE REMIND TRIAL: MULTI-ANTIGEN TARGETED T CELLS FOR PEDIATRIC CNS TUMORS

N. Zhang, P. Hanley, C. Bollard, 2020, Neuro-Oncology.

Antiviral cellular therapy for enhancing T-cell reconstitution before or after hematopoietic stem cell transplantation (ACES): a two-arm, open label phase II interventional trial of pediatric patients with risk factor assessment

Elias T. Zambidis, S. Pai, P. Hanley, 2024, Nature communications.

Hexaviral specific T-cells targeting parainfluenza, CMV, EBV, adenovirus, HHV6 and BKV used for prophylaxis and treatment of viral infections in patients post stem cell transplant

N. Zhang, P. Hanley, C. Bollard, 2019, Cytotherapy.